$43M raised by Clover Biopharmaceuticals in Series B Funding

Based in China, the global clinical-stage bio-tech company Clover Biopharmaceuticalsis focusing on innovative biologic therapies, sealed a US$ 43m (RMB 304m) Series B financing.

Lead by Delos Capital and Lapam Capital, along with some help by from Betta Capital, Sichuan Health Care Indu...